AstraZeneca and Daiichi Sankyo's TROP2-targeting drug Datroway has been approved by the European Commission for some previously untreated patients with metastatic triple-negative breast cancer (TNBC), ...

The patient access system isn't broken because people wanted it to fail. It's broken because it was built for an era where the phone and fax machine were the only universal interfaces, and business ...

IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...

According to a letter (PDF) signed by US Senators Elizabeth Warren (D-Mass), Angela Alsobrooks (D-Md), Richard Blumenthal ...

A woman from the Wirral in the UK has become the first patient in the world to receive an experimental cancer vaccine ...

The European Society for Medical Oncology (ESMO) Annual Congress has long been a bellwether for global oncology trends, and the 2025 meeting in Berlin was no exception. This year’s event showcased a ...

Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of ...

Anti-OX40L antibody amlitelimab was discarded as a treatment for atopic dermatitis last week, and today – during its ...

FDA advisors have voted that Capricor Therapeutics has not provided strong evidence of efficacy for its cell therapy for ...

The once-daily, oral TEC/JAK3 inhibitor has shown efficacy in active and stable nonsegmental vitiligo (NSV) – the most common form of the disease – in which the most common form of vitiligo, ...

AstraZeneca headlined its third-quarter earnings update with news of a $185 million upfront licensing deal with Chinese biotech Eccogene for an orally active GLP-1 agonist drug with potential in ...

Andrew Witty had been CEO of UnitedHealth Group for four years. Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its financial forecasts ...